NQO1‐Responsive Prodrug for in Cellulo Release of Cytochalasin B as Cancer Cell‐Targeted Migrastatic (Small 16/2026)
Researchers introduced BQTML‑CB, an NQO1‑responsive prodrug that releases cytochalasin B inside tumor cells, disrupting actin filaments and halting migration and proliferation. The design exploits the enzyme NQO1, overexpressed in many aggressive cancers, to achieve tumor‑selective activation while sparing NQO1‑deficient cells and neutrophils, thereby reducing systemic toxicity. In vitro studies showed potent anti‑migratory effects across multiple NQO1‑high carcinoma lines with minimal impact on normal cells. The work positions the prodrug as a precision migrastatic with potential for combinatorial cancer therapy.
Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome
Researchers have engineered biomimetic nanocarriers that combine liposomal structures with Myxobacteria outer‑membrane vesicles (OMVs) to deliver antibiotics. The hybrid carriers achieve higher drug loading and can penetrate intracellular Gram‑negative pathogens, while native OMVs avoid immune clearance and sustain extracellular exposure....
Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing
The review surveys nature‑inspired nanocarriers—viral vectors, extracellular vesicles, liposomes, lipid nanoparticles, and engineered membrane particles—as delivery platforms for CRISPR genome editors. It details how these systems improve editing specificity, lower immunogenicity, and surmount cellular barriers that have limited therapeutic rollout....
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
The FDA issued a third complete response letter rejecting Aldeyra Therapeutics' lead dry‑eye candidate, reproxalap, citing a lack of substantial evidence and inconsistent efficacy data. The agency noted the drug failed to demonstrate clear benefit in well‑controlled studies, though no...
Can Bristol Myers Squibb’s Pipeline Strategy Offset a Major Patent Cliff?
Bristol Myers Squibb faces a major patent cliff as flagship drugs like Revlimid, Pomalyst, Opdivo and Eliquis lose exclusivity, threatening its revenue base. To counteract the decline, the company is reshaping its pipeline through internal R&D and high‑profile acquisitions, emphasizing...
Are Pig Organs the Future of Transplantation?
The United States faces a transplant shortage of over 100,000 patients, prompting research into xenotransplantation using genetically engineered pig organs. Recent cases—David Bennett’s pig heart in 2022, Lawrence Faucette’s in 2023, and Tim Andrews’ pig kidney in 2025—demonstrate feasibility, with...
NVIDIA and Persistent Systems Partner to Bring ‘Agentic AI’ to Drug Discovery
Persistent Systems has partnered with NVIDIA to bring Agentic AI to the healthcare and life‑sciences sector, focusing on computational drug discovery. Leveraging NVIDIA’s full AI stack—including AI Enterprise, BioNeMo, the NeMo Agent Toolkit, and NIM microservices—Persistent built GenMolVS, a generative...
EMA Marketing Authorization of New Drugs in February 2026
In February 2026 the European Commission and the CHMP granted marketing authorisations and positive opinions for a slate of innovative therapies spanning COVID‑19, oncology, cardiology, immunology and rare diseases. Notable approvals include Moderna’s mNEXSPIKE COVID‑19 vaccine, Hansoh’s Aumseqa for EGFR‑mutated...
FreezOpt Controls Ice Nucleation, Preserves Cells in Cryopreservation
I've always been fascinated by animals that can survive being frozen—cell walls are delicate and can be destroyed by ice crystals. HOHCells just launched FreezOpt, which is designed to keep cells intact during cryopreservation. It enables controlled initiation of ice...
For Newer Sepsis Diagnostics, What the Studies Show
Newer sepsis diagnostics such as monocyte distribution width (MDW), Intellisep, and MeMed BV are showing promise in early clinical studies but each has distinct limitations. MDW, available on the Beckman Coulter CBC platform, improves sepsis detection when combined with white‑blood‑cell...
Blood Test Detects Brain Tumours with 90% Accuracy
Scientists at the University of Manchester have developed a blood test that detects brain tumours with 90% accuracy by measuring a pair of proteins. The test, validated in glioblastoma patients, is being evaluated in a multi‑site clinical trial across six...
DDW Highlights: 17 March 2026
In this DDW Highlights episode, Bruno Quinney reviews four major stories: a Mayo Clinic study linking the Parkinson's protein alpha‑synuclein to dramatically faster Alzheimer’s progression in women; a Texas A&M‑funded project testing extracellular vesicle (EV) therapy to modulate microglia and...
Cancer Vaccines Could Transform Treatment and Prevention – but Misinformation About mRNA Vaccines Threatens Their Potential
Scientists are accelerating development of mRNA cancer vaccines, with more than 120 clinical trials targeting melanoma, brain, breast, lung and prostate tumors. Early studies, such as personalized vaccines for glioblastoma, demonstrate rapid immune activation and improved survival. Simultaneously, a false...
Peptide Drugs Require Robust Safety and Efficacy Evidence
In response to suggesting peptide drugs should have good evidence on safety and efficacy in order to weigh the risks and benefit…
Designing Clinical Trials to Address Asthma and COPD Flare-Ups
Acute asthma and COPD exacerbations remain a costly, life‑threatening gap despite advances in chronic therapies. Connect Biopharma, led by Barry Quart, is the first biotech targeting these flare‑ups with a biologic that blocks IL‑4Rα, aiming to curb upstream inflammation. The...
R1: China-to-U.S. NewCo Planning Global Testing of New CKD Mechanism
The article outlines BioCentury’s cookie policy, detailing categories of cookies used on its website. Strictly necessary cookies are always active and enable authentication, registration, and core navigation. Functional, marketing, advertising, and analytics cookies provide personalization, targeted promotions, ad tracking, and...
Huntington’s Disease Gene Therapy: FDA Reversal Delays AMT-130
A Phase I/II trial of AMT‑130, an AAV‑delivered microRNA gene therapy, showed a 75% reduction in Huntington's disease progression over three years in 12 patients. The FDA initially supported using external control data from the Enroll‑HD database for the Biologics...
Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective
The blog by HotSpot Therapeutics CEO Jonathan Montagu argues that China is no longer just a manufacturing hub but a burgeoning source of innovative drug candidates, evidenced by its 17% lead over the U.S. in Nature’s Index and nearly half...
Evidence for Microglia to Actively Promote Amyloid Aggregation in the Aging Brain
Researchers have discovered that microglia, the brain’s innate immune cells, can actively remodel soluble amyloid‑β (Aβ42) into extracellular fibrils with strong seeding activity, contrary to the prevailing view that they only clear plaques. Cell‑based assays showed that microglia‑generated amyloid closely...
GEN Secures BEBO Foundation Approval for Phase II PD Trial
GEN Pharmaceuticals received BEBO Foundation ethical approval to launch a Phase II proof‑of‑concept trial of its mitochondrial‑targeting drug SUL‑238 in Parkinson’s disease. The single‑centre, randomised, double‑blind, placebo‑controlled study, named SHEPHERD, will begin patient enrolment in Groningen in April 2026. Over a 28‑day...
Modified Lipid Nanoparticles Boost Immunity and Cut Vaccine Inflammation
Engineered lipid nanoparticles with modified ionizable lipids enhance immune cell metabolism, improve mRNA vaccine delivery to lymph nodes, and reduce inflammatory side effects in preclinical models. vaccinetechnology
Single-Cell Analysis Advances Neurodegenerative Disease Understanding
Neurodegenerative diseases at the single-cell level, a powerful tool to differentiate and better understand https://t.co/Pkz4qW0ELM @jclinicalinvest https://t.co/LiJ4FojRYZ
NeuroScientific Readies Stem Cell Supply Boost for Bowel Disease Trials
NeuroScientific Biopharmaceuticals has begun its first manufacturing run of the StemSmart mesenchymal stem cell therapy at Q‑Gen Cell Therapeutics in Brisbane, initiating a critical technology transfer. The engineering run will validate quality, potency and regulatory compliance ahead of a Phase 2...
CytomX CRC Data Demand Double‑Take, Not Clear Verdict
Some clinical updates tell you exactly what they are. Others ask to be read twice. CytomX’s latest CRC data belong firmly in the second category. Is the die cast? https://t.co/dfdPxx4zXs https://t.co/y9QAoahMut
Co‑varying Residues in MSAs Predict Protein Contact Points
A great read: What we can learn from evolving proteins "A signal hidden in Mulitple Sequence Alignments (MSAs): amino acid positions that tend to co-vary in the MSA tend to interact with each other in the folded structure, often via direct...
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics reported its Q4 2018 results, highlighting progress on its lead cell therapy EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The Phase 1/2 trial demonstrated continuous type VII collagen expression for over two years, a favorable safety profile, and durable wound...
Hidden Mistakes, Not Bad Data, Threaten Genomics
1/ You think the biggest danger in genomics is bad data. More than that. It's the mistakes you make—without knowing. Here are the ones I learned the hard way. 🧵 https://t.co/3oj9cseVq7
R1 Secures $78M to Advance Kidney Drug Development
R1 starts up with $78M, aiming for a better kidney drug https://t.co/PQQjX47ODM by @gwendolynawu #biotecjh #startups
Cibus Inc (CBUS) Q4 2025 Earnings Call Transcript
Cibus reported a $9.9 million cash balance and a $22.3 million capital raise that extends its runway into late 2026. Operating expenses were trimmed by roughly $10 million, though the quarter posted a $31.9 million net loss. The company highlighted a $200 million royalty opportunity...
New Drug Could Eradicate Sleeping Sickness, Says NPR
Sleeping sickness could be wiped out with this new drug: my comments @NPR @NPRGlobalHealth https://t.co/T0mAeX8P0A
Vote for the Top Engineered Yeast Bioart
It’s time for the annual vote for best engineered yeast bioart from the @ImperialBioeng undergrad #SynBio students. Help us decide among these beautiful final 4 with your votes. 🗳️ ⬇️ https://t.co/2fo1XaGCmL
ION717 Trial Re-Opens with 3rd Dosing Regimen
Ionis Pharmaceuticals announced that its Phase 1/2a PrProfile trial of ION717, the first PrP‑lowering antisense oligonucleotide for symptomatic prion disease, has reopened with a third dosing regimen. The study, which enrolled 56 patients in 2024, will now recruit at three...
Seeking Examples of Overly Negative Biotech Trade Press
Will ask colleagues to respond because I haven’t been tracking all the tickers. Pls reply with examples of biotech trade press being called too negative
Light-Controlled Hydrogel Mimics Soft Human Tissue for More Realistic Cell Studies
Researchers at the University of Colorado Boulder have created a light‑controlled hydrogel that closely replicates the softness and viscoelastic behavior of human tissue. The material can be solidified or softened on demand using photopolymerization, allowing precise spatial control during 3‑D...
FDA Drug Safety Communication: Updated Drug Labels for Pioglitazone-Containing Medicines
The FDA has approved updated labeling for all pioglitazone‑containing medicines, adding a warning that use longer than one year may increase bladder cancer risk. Healthcare professionals are instructed not to prescribe pioglitazone to patients with active bladder cancer and to...
FDA Drug Safety Communication: FDA Approves Label Changes for Use of General Anesthetic and Sedation Drugs in Young Children
The FDA has approved label changes for general anesthetic and sedation drugs used in children under three, adding a warning that prolonged exposure—more than three hours or multiple procedures—may harm brain development. The revisions incorporate animal study data showing neuronal...
Broken Chromosomes Repaired with Fragments Spark Cancer‑driving Mutations
Researchers at Cardiff University found that severe DNA mutations called chromoanasynthesis happen when broken chromosomes are repaired using small DNA fragments, causing chaotic duplications that can drive cancer and genetic diseases. 🧬https://t.co/Q9j2hRezTs
Frog-Cell 'Neurobots' Grow Self-Organized Nervous Systems and Alter Gene Activity
Researchers at the Wyss Institute have created the first “neurobots,” living robots built from frog embryonic cells that incorporate neuronal precursor cells to form self‑organizing nervous systems. The neurobots develop mature neurons that connect internally and extend processes to surface...
Judge Stalls Kennedy Childhood Vaccine Overhaul Meeting
Kennedy childhood vaccine overhaul stalled by judge The next meeting of the Advisory Committee on Immunization Practices was scheduled for this week, but has been postponed due to the ruling https://t.co/0cUIXEVgyV
Millions of Protein Complexes Added to AlphaFold Database Shed Light on How Proteins Interact
A joint effort by EMBL‑EBI, Google DeepMind, NVIDIA and Seoul National University has added millions of AI‑predicted protein complex structures to the AlphaFold Database, marking the largest collection of such data to date. The release focuses on high‑confidence homodimers, delivering...
IDT Unveils NGS Portfolio
Integrated DNA Technologies (IDT) announced a new next‑generation sequencing (NGS) portfolio that includes the DNA EZ v2 library preparation kit, the xGen Exome v2 Hyb spike‑in panel, a 1,536‑member set of full‑length unique dual‑index adapters, and an upgraded whole‑genome sequencing system. The suite targets...
Illumina Launches Software for Multiomic Analysis
Illumina unveiled Illumina Connected Multiomics, a cloud‑based platform that unifies single‑cell, spatial transcriptomics, proteomics, and methylation data for large‑scale analysis. The system aggregates thousands of samples from Illumina and third‑party assays, delivering reproducible results through DRAGEN secondary analysis. AI‑driven tools...
FDA Clears Cepheid Xpert GI Multiplex PCR Test
Cepheid’s Xpert GI panel received FDA clearance, offering a multiplex PCR test that identifies 11 bacterial, viral, and parasitic gastrointestinal pathogens from a single stool sample. The assay delivers results in roughly 74 minutes and operates on the existing GeneXpert...
FDA Clears Copan PhenoMatrix Software
The U.S. Food and Drug Administration granted 510(k) clearance to Copan Group’s PhenoMatrix, an AI‑driven image‑assessment tool that runs on the WASPLab automation platform. Classified as a class II device, the software automatically sorts and evaluates bacterial culture plate images across...
Methionine Restriction Cuts Alzheimer Pathology via FGF21 Signaling
A study in Alzheimer's & Dementia found that late-life methionine restriction reduces Alzheimer’s pathology and neuroinflammation in mice by activating the liver–brain FGF21–FGFR1 signaling pathway, independent of metabolic improvements. 🧠 https://t.co/A9kEqNv8pO
Ultrasound-Activated Nanoparticles Breach Bacterial Biofilms
Scientists have engineered silica‑based nanoparticles that encapsulate rifampicin and release it only when exposed to low‑frequency ultrasound. The ultrasound both propels the particles through the protective matrix of bacterial biofilms and triggers cavitation that opens the particles, delivering the antibiotic...
Semaglutide Boosts Metabolism, Reduces Anxiety in Obese Mice
Beyond the Weight Loss: The Effects of Semaglutide on Standard and Diet-Induced Obese Mice 🤔"..semaglutide improved glucose metabolic health inboth diet groups..while chronic semaglutide treatment appeared to exertanxiolytic effects in obese mice, opposit[e] effects were observed in lean animals.." https://t.co/doU6EkwT7z
AI and Genomics: A New Era of Personalized Medicine
Artificial intelligence is reshaping genomics by speeding up sequencing and uncovering patterns that traditional tools miss, enabling truly personalized medicine. AI models can predict disease risk, suggest optimal therapies, and guide tumor classification, especially in oncology and emerging mRNA vaccine...
Interfering in Induction of Bystander Senescence as an Approach to Senotherapy
Researchers have mapped how senescence spreads between human brain cell types via the senescence‑associated secretory phenotype (SASP). Using DNA‑damage‑induced cultures and conditioned‑media assays, they identified cell‑type‑specific SASP signatures that drive secondary senescence in neighboring astrocytes, endothelial cells, microglia, oligodendrocytes and...
How Synergy Spine Engineered Its New Cervical Disc for Mobility and Alignment
Synergy Spine Solutions secured FDA pre‑market approval for its Synergy Disc, the first artificial cervical disc that simultaneously improves spinal alignment and preserves full range of motion. The device features a patented interrupted‑articulation geometry that creates a low‑energy, lordotic position...